A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Clinical trial NCT05601882 · COMPLETED

Trial details

NCT number: NCT05601882
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2022-11-28
Primary completion: 2024-03-19
Enrollment: 920

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.